Successful results of a University of Liverpool-led trial that utilised nanotechnology to improve drug therapies for HIV patients has been presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, a leading annual conference of HIV research, clinical practice and progress.
The healthy volunteer trial, conducted by the collaborative nanomedicine research programme led by Pharmacologist Professor Andrew Owen and Materials Chemist Professor Steve Rannard, and in collaboration with the St Stephen’s AIDS Trust at the Chelsea & Westminster Hospital in London, examined the use of nanotechnology to improve the delivery of drugs to HIV patients. The results were from two trials which are the first to use orally dosed nanomedicine to enable HIV therapy optimisation.
Manipulation of matter
Nanotechnology is the manipulation of matter on an atomic, molecular, and supramolecular scale. Nanomedicine is the application of nanotechnology to the prevention and treatment of disease in the human body. By developing smaller pills that are better for patients and less expensive to manufacture, this evolving discipline has the potential to dramatically change medical science and is already having an impact in a number of clinically used therapies and diagnostics worldwide.
Currently, the treatment of HIV requires daily oral dosing of HIV drugs, and chronic oral dosing has significant complications that arise from the high pill burden experienced by many patients across populations with varying conditions leading to non-adherence to therapies.
Developing new therapies
Recent evaluation of HIV patient groups have shown a willingness to switch to nanomedicine alternatives if benefits can be shown. Research efforts by the Liverpool team have focused on the development of new oral therapies, using Solid Drug Nanoparticle (SDN) technology which can improve drug absorption into the body, reducing both the dose and the cost per dose and enabling existing healthcare budgets to treat more patients.
The trial results confirmed the potential for a 50 percent dose reduction while maintaining therapeutic exposure, using a novel approach to formulation of two drugs: efavirenz (EFV) and, lopinavir (LPV). EFV is the current WHO-recommended preferred regimen, with 70% of adult patients on first-line taking an EFV-based HIV treatment regimen in low- and middle-income countries.
The trial is connected to the University’s ongoing work as part of the multinational consortium OPTIMIZE, a global partnership working to accelerate access to simpler, safer and more affordable HIV treatment. Funded by the U.S. Agency for International Development, OPTIMIZE is led by the Wits Reproductive Health & HIV Institute in Johannesburg, South Africa, and includes the interdisciplinary Liverpool team, Columbia University, Mylan Laboratories and the Medicines Patent Pool (MPP). OPTIMIZE is supported by key partners including UNITAID and the South African Medical Research Council (SAMRC).
Benny Kottiri, USAID’s Office of HIV/AIDS Research Division Chief, said: “The potential applications for HIV treatment are incredibly promising. By aligning efforts, these integrated investments offer the potential to reduce the doses required to control the HIV virus even further, resulting in real benefits globally. This would enable the costs of therapy to be reduced which is particularly beneficial for resource-limited countries where the burden of disease is highest.”
To watch the presentation please click here.
Receive an email update when we add a new HIV article.
The Latest on: HIV
via Google News
The Latest on: HIV
- Fulton County receives multi-million dollar grant to fight HIVon September 7, 2019 at 9:44 am
ATLANTA — Fulton County is combating HIV with a new, multi-million-dollar federal grant. The $2.5 million federal grant from The Substance Abuse and Mental Health Services Administration will serve ...
- Infant model of HIV opens new avenues for researchon September 6, 2019 at 5:17 pm
Researchers have developed an animal model to test HIV infection and therapies in infants, allowing them to develop biomarkers to predict viral rebound after antiretroviral therapy (ART) interruption.
- New Research Is Final Blow To An HIV Cure That Wasn'ton September 6, 2019 at 3:12 pm
A series of animal and human studies published this week are providing a sad footnote to a controversial 2016 experiment in monkeys that pointed to a possible cure for HIV but was later flagged for a ...
- Kick HIV Care Out of the Clinicon September 6, 2019 at 1:49 pm
WASHINGTON, DC — More than 50 protesters chanting "You can't end this without us" stormed the stage here at the United States Conference on AIDS 2019 after a presentation on the Ending the HIV ...
- Spate of clinical trials has scientists hopeful about a vaccine to prevent HIVon September 6, 2019 at 8:41 am
First there were the drugs that could knock back HIV to undetectable levels, and the virus was no longer synonymous with a death sentence. Then came a treatment that allowed people who were HIV ...
- Canadian children undergo HIV testing after being pricked with discarded needle at schoolon September 6, 2019 at 6:15 am
A Canadian mother is cautioning other parents after multiple children — including her daughter — were pricked by potentially infected needles at their school. Amy Slater took to Facebook Wednesday ...
- HIV prevention is making progress. And a breakthrough vaccine appears within reachon September 6, 2019 at 6:08 am
First there were the drugs that could knock back HIV to undetectable levels, and the virus was no longer synonymous with a death sentence. Then came a treatment that allowed people who were ...
- Three teams fail to replicate results of 2016 HIV study that claimed 'cure' in monkeyson September 6, 2019 at 6:02 am
Three separate and independent teams of researchers have attempted to replicate the results of a team which, back in 2016, claimed to have cured monkeys of an HIV-like infection. All three have ...
- Pope Francis visits HIV-sufferers on Maputo's outskirtson September 6, 2019 at 5:09 am
Pope Francis on Friday (September 6), his final day in Mozambique, visited a hospital on the outskirts of Maputo which treats HIV-AIDS-infected mothers and their children. Rough cut (no reporter ...
via Bing News